What the 2011 Census of India Reveals for Pharma - The census reveals the state of the population of India's health and the potential for growth in the healthcare market. Part of a special outsourcing


What the 2011 Census of India Reveals for Pharma
The census reveals the state of the population of India's health and the potential for growth in the healthcare market. Part of a special outsourcing section.

BioPharm International
Volume 25, Issue 2, pp. 27-30


Yet India continues to fare poorly in comparison with global averages. On the broad social indicator scale, India is ranked a mediocre 119 out of 169 countries on the United Nations Development Program's (UNDP) Global Human Development Index 2010.

In fact, if India is compared against other emerging countries, it is way behind China. Government expenditure on healthcare in China is nearly five times that in India. Although China has a larger population and a higher per capita income than India, the Chinese government spends nearly 2% of GDP on healthcare, while in India it is only slightly above 1%.

In a report on "Quality of Life" between the two Asian nations, Amartya Sen, the Nobel Prize winner in Economics in 1998, cited the 2011 census data in noting that life expectancy at birth in China is 73.5 years, while in India it is 64.4 years. Infant mortality rate is 50 per 1000 births in India, as compared with just 17 in 1000 births in China. The mortality rate for children under five years of age is 66 per 1000 for Indians and 19 in 1000 for the Chinese. Sen also noted that only 66% of Indian children are immunized with triple vaccine (i.e., diphtheria/pertussis/tetanus), as opposed to 97% percent in China.


As part of the census exercise, the government is launching its first national health survey in which information on blood pressure, blood grouping, sugar levels, and other basic primary-care indicators are to be collected, to help identify predisposing disease factors. This data will be collected directly at the community and even neighbourhood level, with the aim of close targeting of healthcare policies relevant to affected populations as well as gaining guidance in deciding Union Budget priorities. Pharmaceutical companies should watch this exercise closely as it will shape the coming debate on expanding government investments in a basic healthcare system linked to a commitment to universal coverage.

Progress has also been posted in basic health indicators such as sanitation. An interesting tidbit revealed at the last census was that India had more households owning television sets than those with bathrooms. Likewise, while the 2001 census found that 68% of the population had access to clean drinking water. Today, the figures stand at 94% for rural dwellers and 91% for urban residents.

Nevertheless, some 37.7 million Indians are affected by waterborne diseases annually, 1.5 million children are estimated to die of diarrhea, and 73 million working days are lost due to waterborne disease each year. Treating these diseases costs the strained public health system in excess of $600 million per year, which could be ameliorated by new investments in health infrastructure.

The census exercise has been useful in helping drive awareness that India needs to invest more in health. Whether it will do this successfully depends on political factors that are hard to assess at the present time.

Mangeshi Sai is a reporter based in India.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here